Syngene extends BMS research collaboration until 2035

Business Updates View source PDF Explain this filing

SYNGENE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹625.50

prior close

₹621.45

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.1%+1.4% vs market

Healthcare Services peers, median of 55sector · industry level-1.2%+1.4% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Smallcap 250 and 1.4 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.1

15m

-0.0

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-1.1+1.4-1.2+1.4

Next day

-3.4-3.8+0.3-3.0-0.4

-3.8-4.5+0.7-4.1+0.3

-5.9-3.6-2.2-3.3-2.6

-13.7-5.5-8.2-5.4-8.3

-22.0-5.3-16.7-5.8-16.2

-24.4-3.6-20.8-6.7-17.7

15d

-27.4+0.9-28.3-0.7-26.7

-30.0-1.4-28.6-0.9-29.1

-34.7-9.0-25.8-8.8-25.9

-30.5+1.1-31.5-1.5-28.9

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Services peers, median of 55Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Syngene International has extended its long-term research collaboration with Bristol Myers Squibb through 2035. The partnership began in 1998 and spans over 25 years. The expanded agreement broadens integrated services across the drug development lifecycle, from discovery and translational sciences to pharma development, manufacturing, clinical trials, and data services. The BBRC center, with around 700 Syngene scientists, supports BMS across cardiovascular, fibrosis, immunology, and oncology.

Likely market impact

Positive: 10-year extension of a 25-plus year partnership with a key global pharma client, providing revenue visibility and reinforcing Syngene's CRDMO position.